NEW YORK (GenomeWeb News) - Compugen today said it has signed a collaboration with Teva Pharmaceuticals to discovery biomarkers that could predict nephrotoxicity.
The agreement also may be expanded to include biomarker development for hepatoxicity and cardiotoxicity, Compugen said.
Under the agreement, Compugen will use its computational tools and nucleic acid testing technologies to analyze biological samples collected by Teva in a preclinical study.
Teva will have a license to use the discovered markers for its internal R&D programs, while Compugen has retained rights to license the markers to other companies, as well as rights for internal use.
Ana Cohen-Dayag, Compugen’s vice president of diagnostic biomarkers, said in a statement that the company will use predictive platforms it developed for immunoassay diagnostic collaborations to develop the biomarkers, which will enable early-stage identification of toxicity.